Recent Report on Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016

Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape.

Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor. GBMs arise from glial cells, which are cells that form the tissue that surrounds and protects other nerve cells found within the brain and spinal cord. GBMs are mainly composed of star-shaped glial cells known as astrocytes. Signs and symptoms include slowly progressive neurologic deficit, usually motor weakness, headache, generalized symptoms of increased intracranial pressure, including headaches, nausea and vomiting, and cognitive impairment and seizures. Treatment includes radiation therapy and chemotherapy.

Complete report available @ Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Glioblastoma Multiforme (GBM) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glioblastoma Multiforme (GBM) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 11, 98, 53, 1, 4, 147, 18 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 8, 12, 1, 35 and 8 molecules, respectively.

Glioblastoma Multiforme (GBM) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Glioblastoma Multiforme (GBM) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Glioblastoma Multiforme (GBM) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

AbbVie Inc Activartis Biotech GmbH Advanced Accelerator Applications SA Advantagene Inc Advenchen Laboratories LLC Affimed GmbH Agenus Inc Amal Therapeutics SA Ambrx Inc Amgen Inc Ampio Pharmaceuticals Inc AngioChem Inc Apac Biotech Pvt Ltd Apceth GmbH & Co KG APIM Therapeutics AS Apogenix GmbH Ariad Pharmaceuticals Inc Arog Pharmaceuticals Inc Astellas Pharma Inc AstraZeneca Plc Athenex Inc Axelar AB Basilea Pharmaceutica Ltd Batu Biologics Inc Bayer AG BeiGene Ltd Bexion Pharmaceuticals LLC BeyondSpring Pharmaceuticals Inc Bio-Path Holdings Inc Bioasis Technologies Inc BioCancell Ltd Biomar Microbial Technologies Bioncotech Therapeutics SL Biovista Inc Boehringer Ingelheim GmbH Boston Biomedical Inc Bristol-Myers Squibb Company BTG Plc Cantex Pharmaceuticals Inc Cavion LLC Celgene Corp Cell Medica Ltd Celldex Therapeutics Inc Celsion Corp ChemoCentryx Inc CLL Pharma SA Coherus BioSciences Inc Cortice Biosciences Inc Critical Outcome Technologies Inc CTI BioPharma Corp Curadev Pharma Pvt Ltd Cynata Therapeutics Limited CytoVac A/S CytRx Corp Deciphera Pharmaceuticals LLC DEKK-TEC Inc DelMar Pharmaceuticals Inc Diffusion Pharmaceuticals Inc Dr. Reddy's Laboratories Ltd Ecrins Therapeutics SAS EirGenix Inc Eisai Co Ltd Eli Lilly and Company EnGeneIC Ltd EntreChem SL ERC Belgium SA Evotec AG F. Hoffmann-La Roche Ltd FirstString Research Inc Five Prime Therapeutics Inc Gene Techno Science Co Ltd Genentech Inc Genisphere Inc Genor BioPharma Co Ltd Genzyme Corp GlaxoSmithKline Plc GtreeBNT Co Ltd GW Pharmaceuticals Plc Hamlet Pharma AB Hutchison MediPharma Ltd Immatics Biotechnologies GmbH Immune Pharmaceuticals Inc ImmunoCellular Therapeutics Ltd Immunomedics Inc Immunomet Therapeutics Inc Immunomic Therapeutics Inc Immupharma Plc Incuron LLC Incyte Corp Infinity Pharmaceuticals Inc Inspyr Therapeutics Inc INSYS Therapeutics Inc Intica Biomedical Inc Jiangsu Kanion Pharmaceutical Co Ltd Johnson & Johnson Kadmon Corp LLC Kalgene Pharmaceuticals Inc KaloBios Pharmaceuticals Inc Karyopharm Therapeutics Inc Kite Pharma Inc Komipharm International Co Ltd Lentigen Technology Inc Les Laboratoires Servier SAS LinXis BV Lion Biotechnologies Inc Lixte Biotechnology Holdings Inc Loxo Oncology, Inc. Mabion SA MacroGenics Inc Mateon Therapeutics Inc Medicenna Therapeutics Inc MedImmune LLC Merck & Co Inc Merck KGaA Midatech Pharma Plc Millennium Pharmaceuticals Inc MimiVax LLC Moleculin Biotech Inc Mycenax Biotech Inc Nanomerics Ltd Neonc Technologies Inc Nerviano Medical Sciences Srl Neumedicines Inc Neuralstem Inc NewLink Genetics Corp Northwest Biotherapeutics Inc Novartis AG Novogen Ltd Noxxon Pharma AG Nuo Therapeutics Inc NuvOx Pharma LLC Omniox Inc Oncobiologics Inc Oncodesign SA Onconova Therapeutics Inc Oncternal Therapeutics Inc Ono Pharmaceutical Co Ltd Orphagen Pharmaceuticals Inc Orphit SAS Oryx GmbH & Co KG Peloton Therapeutics Inc Peregrine Pharmaceuticals Inc Pfizer Inc PharmAbcine Inc PharmaCyte Biotech Inc Pharmicell Co Ltd PIQUR Therapeutics AG Plex Pharmaceuticals Inc Plexxikon Inc Prana Biotechnology Ltd Progenics Pharmaceuticals Inc Puma Biotechnology Inc Recepta Biopharma SA Regulus Therapeutics Inc ReNeuron Group Plc Rexahn Pharmaceuticals Inc Rgenix Inc Richter Gedeon Nyrt Rigontec GmbH Sanofi Sapience Therapeutics Inc Scancell Holdings Plc Sellas Inc Sigma-Tau SpA SignPath Pharma Inc SOM Biotech SL Sorrento Therapeutics Inc StemGen SpA Stemline Therapeutics Inc Sumitomo Dainippon Pharma Co Ltd Susavion Biosciences Inc Symphogen A/S Takeda Pharmaceutical Company Ltd Terpenoid Therapeutics Inc Therapeia GmbH & Co KG Theravectys SA Threshold Pharmaceuticals Inc Tocagen Inc TRACON Pharmaceuticals Inc Transgene SA Trillium Therapeutics Inc TVAX Biomedical Inc Tyme Technologies Inc Upsher-Smith Laboratories Inc Vascular Biogenics Ltd Vault Pharma Inc Vaximm AG VBI Vaccines Inc VCN Biosciences SL Vertex Pharmaceuticals Inc ViraTherapeutics GmbH Virttu Biologics Ltd Vyriad Inc X4 Pharmaceuticals Inc ZIOPHARM Oncology Inc

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

ReportstackMarket Research

###